|Raising the bar on data and biosample sharing from AD/ADRD clinical trials|
|Laurie Ryan, Chief, Clinical Interventions and Diagnostics Branch, and Suzana Petanceska, Director, Office for Strategic Development and Partnerships, Division of Neuroscience|
NIA’s increased funding for Alzheimer’s disease and related dementias (AD/ADRD) research has allowed the continued expansion and diversification of our drug development portfolio and translational infrastructure programs to help advance future therapeutics.
Implementing best practices for sharing data, methods, and biosamples is at the core of NIA’s next-generation clinical trials infrastructure. If you are working on a clinical trial application, be sure to plan ahead, budget, and communicate with your program officer on how you will approach data and biosample sharing! Read the full blog post.